TESTOSTERONE REPLACEMENT

Testosterone Replacement Therapy Now Available in New Dosage

May 5, 1997 -- SmithKline Beecham and TheraTech, Inc. announced that a new 5 milligram per day formulation of Androderm® (Testosterone Transdermal System), has been cleared for marketing by the U.S. Food and Drug Administration (FDA). Androderm is the only non-scrotal patch available in the U.S. to treat male hypogonadism or testosterone deficiency. It was originally marketed as a two-patch, 2.5 milligram (mg) system. Click for more details

GROWTH HORMONE

Genotropin Pen 12 Growth Hormone Delivery Device Now Available in U.S.

April 11 , 1997 -- Genotropin Pen 12, a delivery system for Genotropin lyophilized powder (somatropin [rDNA origin] for injection) is now available in the United States. The Genotropin Pen 12 model provides greater dosing flexibility (up to 4 mg per injection) than the Genotropin Pen 5, introduced in 1996. Click for more details

DIABETES INSIPIDUS

RPR Launches DDAVP Tablets For Central Diabetes Insipidus (CDI)

Feb. 8, 1996 -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) today announced that it has received Food and Drug Administration (FDA) clearance to market a tablet formulation of DDAVP (desmopressin acetate) for the treatment of central diabetes insipidus (CDI). DDAVP is a synthetic analog of vasopressin, an antidiuretic hormone affecting renal water conservation. Click for more details

TESTOSTERONE - HYPOGONADISM

Androderm Is Now Available Nationwide

Nov. 29, 1995 - SmithKline Beecham (NYSE: SBH) and TheraTech, Inc. (Nasdaq: THRT) announced today that Androderm® (Testosterone Transdermal System) is now available nationwide. Androderm is a treatment for men suffering from hypogonadism, a condition in which the body produces insufficient levels of testosterone. The product, available only by a doctor's prescription, was cleared for marketing by the U.S. Food and Drug Administration (FDA) in late September 1995. Click for more details.

TESTOSTERONE REPLACEMENT

Androderm Cleared by FDA for Testosterone Replacement Therapy

Oct. 2, 1995 - SmithKline Beecham (NYSE: SBH) and TheraTech, Inc. (Nasdaq: THRT) today announced that Androderm® (Testosterone Transdermal System) has been cleared for marketing by the U.S. Food and Drug Administration (FDA) as a treatment for men suffering from hypogonadism, a condition in which the body produces insufficient levels of testosterone. Only about 250,000 of the estimated four to five million American men of all ages with hypogonadism currently receive testosterone replacement therapy. Click for more details.